Effect of once-weekly semaglutide on functional capacity in patients with peripheral arterial disease and type 2 diabetes: results from the STRIDE study

Czech version

Authors: Michal Vrablík
Authors‘ workplace: Centrum preventivní kardiologie, III. interní klinika – endokrinologie a metabolismu 1. LF UK a VFN v Praze
Published in: AtheroRev 2025; 10(2): 116-119
Category: Reviews

Overview

Peripheral arterial disease (PAD) is a major health complication in patients with type 2 diabetes (T2DM), leading to poorer quality of life, increased morbidity and mortality. Treatment options aimed at improving physical performance are limited. The STRIDE study evaluated the efficacy of semaglutide 1.0 mg once weekly on functional capacity and quality of life in patients with PAD and T2DM. In a 52-week, randomized, double-blind, placebo-controlled study, semaglutide was shown to significantly improve the maximum and pain-free distance a patient is able to walk as well as metabolic parameters and quality of life without significant safety risks. The results suggest the potential of semaglutide as a comprehensive therapeutic option in this high-risk population.

Keywords:

semaglutide – type 2 diabetes mellitus (T2DM) – peripheral arterial disease (PAD)

Sources

Mazzolai L, Teixido-Tura G, Lanzi S et al. [ESC Scientific Document Group]. 2024 ESC guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J 2024; 45(36): 3538–3700. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehae179>.

Verma S, Leiter LA, Mangla KK et al. Epidemiology and burden of peripheral artery disease in people with type 2 diabetes: a systematic literature review. Diabetes Ther 2024; 15(9): 1893–1961. Dostupné z DOI: <http://dx.doi.org/10.1007/s13300–024–01606–6>.

Dawson DL. Comparative effects of cilostazol and other therapies for intermittent claudication. Am J Cardiol 2001; 87(12A): 19D–27D. Dostupné z DOI: <http://dx.doi.org/10.1016/s0002–9149(01)01673–3>.

Beebe HG, Dawson DL, Cutler BS et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999; 159(17): 2041–2050. Dostupné z DOI: <http://dx.doi.org/10.1001/archinte.159.17.2041>.

Kosiborod MN, Abildstrøm SZ, Borlaug BA et al. [STEP-HFpEF Trial Committees and Investigators]. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023; 389(12): 1069–1084. Dostupné z DOI: <http://dx.ddoi.org/10.1056/NEJMoa2306963>.

Bonaca MP, Catarig AM, Houlind K et al. [STRIDE Trial Investigators]. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet 2025; 405(10489): 1580–1593. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(25)00509–4>.

Alameddine D, Damara FA, Pinto Rodriguez P et al. The use and impact of cilostazol on patients undergoing endovascular peripheral interventions. Ann Vasc Surg 2024; 103 : 47–57. Dostupné z DOI: <http://dx.doi.org/10.1016/j.avsg.2023.12.071>.

Dawson DL, Cutler BS, Meissner MH et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98(7): 678–86. Dostupné z DOI: <http://dx.doi.org/10.1161/01.cir.98.7.678>.

Lincoff AM, Brown-Frandsen K et al. [SELECT Trial Investigators]. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023; 389(24): 2221–2232. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2307563>.

McGuire DK, Marx N, Mulvagh SL et al. [SOUL Study Group]. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med 2025; 392(20): 2001–2012. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2501006>.

Gerstein HC, Colhoun HM, Dagenais GR et al. [REWIND Investigators]. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394(10193): 121–130. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(19)31149–3>.